Merck’s Molnupiravir Set To Lead Forecast $6bn COVID-19 Oral Antiviral Market

Pfizer and Roche Also In The Running

 
• By Andrew McConaghie

Merck’s antiviral could play a big role, but only if it proves effective in broader settings, such as post-exposure prophylaxis.

Merck
Merck & Co and Ridgeback's antiviral is taken twice a day for 10 days, but must be administered within five days of mild-to-moderate symptoms emerging.

More from Business

More from Scrip